Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 27 October 2016 | By Zachary Brennan
China Food and Drug Administration (CFDA) announced Thursday that its priority review and approval procedure for medical devices will come into force as of 1 January 2017.
The move is part of CFDA’s implementation of reforms to its approval systems for drugs and devices, and to meet the clinical demands of medical devices.
According to the law firm Ropes & Gray, the new policy, first drafted in June, will allow applicants with a Class II device (limited to imported application) or a Class III device (both domestic and imported application) to request a priority review if the device (i) has been enrolled in the National Science and Technology Major Project or National Key Research and Development Plan, or if it can diagnose and treat:
Process for Priority Review
Prior to a device being marketed in China, Class II and Class III devices must go through a technical review process conducted by the Center for Device Evaluation under the CFDA or at the provincial level.
That review assesses whether a device is eligible for priority review, and a decision on the priority review designation will be made before the technical review process begins.
For any application that passes the initial eligibility review, an outside third party may submit an opposition to challenge the result during the public notification period.
For those device applications that receive the priority review designation, companies will be eligible to take advantage of several features, including frequent interactions with the technical review team.
Ropes & Gray also notes that CFDA has already developed two expedited approval processes for devices, including an accelerated approval for devices applicable to emergency public health incidents and a fast track approval for innovative devices.
In addition to the priority reviews, CFDA is also undergoing a major shift in policy on device quality and clinical trials.
Meanwhile, the fast-track scheme for pharmaceuticals is intended to target and prioritize new treatments for cancer, rare diseases, AIDS, tuberculosis and viral hepatitis, as well as those aimed at pediatric and elderly patients.
Tags: China priority reviews for devices, accelerated approval for medical devices
Regulatory Focus newsletters
All the biggest regulatory news and happenings.